Laboratory of Genitourinary Cancer Pathogenesis, CCR
National Cancer Institute
United States of America
Dr. Sowalsky received his Ph.D. from Tufts University's Sackler School of Graduate Biomedical Sciences, performing his dissertation research in the lab of Larry Feig. He conducted postdoctoral training at Harvard Medical School/Beth Israel Deaconess Medical Center with Steven Balk. The central theme of Dr. Sowalsky's research is understanding the biology of the molecular events associated with prostate cancer development, progression, and resistance to therapy.
1) Genomic analysis, 2) functional transcriptomics, 3) pathway analysis, 4) tumor progression, 5) mechanisms of drug resistance, 6) tumor microenvironment, 7) Cancer Biology, 8) Computational Biology, 9) Genetics and Genomics, 10) Molecular Biology and Biochemistry
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.
Gleason Score 7 Prostate Cancers Emerge Through Branched Evolution of Clonal Gleason Pattern 3 and 4.